Health> Vol.4 No.9A, September 2012

The tomography dementia rating scale (TDR)—The rating scale of Alzheimer’s disease stages

DownloadDownload as PDF (Size:669KB)  HTML    PP. 712-719  

ABSTRACT

The purpose of this research is to develop a morphologically determined scale—the Tomography Dementia Rating scale (TDR) to diagnose AD stages, based on the measurement of the severity of voluminal atrophic changes of the temporal lobes of the brain detected among patients during CT and MRI at various stages of the disease. The research included 140 patients aged 28 - 79. Test Group comprised 81 patients aged 34 - 79 suffering from various AD stages. Control Group consisted of 59 patients aged 28 - 78 who had various types of brain lesions with manifestations of dementia and cognitive impairment but who did not suffer from AD. CT and MRI data obtained has made it possible to create a scale that allows determining the severity of atrophic changes in the temporal lobes at each stage of AD development: 1) Pre-clinical AD stage—TDR-0: temporal lobes atrophy with a 4% - 8% decrease in tissue mass (corresponds to 26 - 28 MMSE points); 2) Early AD Stage—mild dementia—TDR-1: temporal lobes atrophy with a 9% - 18% decrease in tissue mass (corresponds to CDR-1 and to 20 - 25 MMSE points); 3) Middle AD stage—moderate dementia—TDR-2: temporal lobes atrophy with a 19% - 32% decrease in tissue mass (corresponds to CDR-2 and to 12 - 19 MMSE points); 4) Late AD stage—heavy dementia—TDR-3: temporal lobes atrophy with a 33% - 62% decrease in tissue mass (corresponds to CDR-3 and to 7 - 11 MMSE points). Thereby, the developed Tomography Dementia Rating scale (TDR) complements the Clinical Dementia Rating scale (CDR) and allows a correct and objective determination of AD stages as well as an easy differentiation of existing lesions with neurodegenerative changes characteristic for other diseases accompanied by dementia and cognitive impairment.

Cite this paper

Maksimovich, I. (2012) The tomography dementia rating scale (TDR)—The rating scale of Alzheimer’s disease stages. Health, 4, 712-719. doi: 10.4236/health.2012.429111.

References

[1] (2007) Alzheimer’s disease facts and figures. Alzheimer’s Association. http://www.alz.org/national/documents/report_2007factsandfigures.pdf
[2] (2009) Alzheimer’s disease facts and figures. Alzheimer’s Association. http://www.alz.org/national/documents/report_alzfactsfigures2009.pdf
[3] (2010) Alzheimer’s disease facts and figures. Alzheimer’s Association. http://www.alz.org/documents_custom/report_alzfactsfigures2010.pdf
[4] (2011) Alzheimer’s disease facts and figures. Alzheimer’s Association. http://www.alz.org/downloads/facts_figures_2011.pdf
[5] (2011) Generation Alzheimer’s: The defining disease of the baby boomers. http://act.alz.org/site/DocServer/ALZ_BoomersReport.pdf?docID=521
[6] Jun, G., Naj, F.C., Beecham, G.M., et al. (2010) Meta-analysis confirms CR1, CLU, and PICALM as Alzheimer disease risk loci and reveals interactions with APOE genotypes. Archives of Neurology, 67, 1473-1484. doi:10.1001/archneurol.2010.201
[7] Saykin, A.J. and Wishart, H.A. (2003) Mild cognitive impairment: Conceptual issues and structural and functional brain correlates. Neuropsychiatry, 8, 12-30. http://www.ncbi.nlm.nih.gov/pubmed/12567329
[8] Saykin, A.J., Wishart, H.A., Rabin, L.A., et al. (2006) Older adults with cognitive complaints show brain atrophy similar to that of amnestic MCI. Neurology, 12, 834-842. http://www.neurology.org/content/67/5/834.abstract
[9] Shen, L.H., Fipri, H.A., Saykin, A.J. and West, J.D. (2009) Parametric surface modeling and registration for comparison of manual and automated segmentation of the hippocampus. Hippocampus, 19, 588-595. doi:10.1002/hipo.20613
[10] Maksimovich, I.V. (2008) Radiodiagnostics of Alzheimer’s disease. Diagnostics and Intervention Radiology, 2, 27-38. http://www.radiology-di.ru/articles/155/126/tom-2-N4-2008.html
[11] Mayeux, R., Reitz, C., Brickman, A., Haan, M.N., Manly, J.J., et al. (2011) Operationalizing diagnostic criteria for Alzheimer’s disease and other age-related cognitive impairment—Part 1. Alzheimer’s & Dementia, 7, 15-34. http://www.ncbi.nlm.nih.gov/pubmed/21255741
[12] Seashadri, S., Beaser, A., Au, R., Volf, P.A., Evans, D.A., et al. (2011) Operationalizing diagnostic criteria for Alzheimer’s disease and other age-related cognitive impairment—Part 2. Alzheimer’s & Dementia, 7, 35-52. http://www.ncbi.nlm.nih.gov/pubmed/?term=Operationalizing%20diagnostic%20criteria%20for%20Alzheimer's%20disease%20and%20other%20age-related%20cognitive%20impairment-Part%202
[13] (2012) Alzheimer’s disease facts and figures. Alzheimer’s Association. http://www.alz.org/downloads/facts_figures_2012.pdf
[14] (2012) National plan to address Alzheimer’s disease. http://www.whitehouse.gov/blog/2012/05/17/national-plan-address-alzheimers-disease
[15] Morris, J.C. (1993) The clinical dementia rating (CDR): Current version and scoring rule. Neurology, 43, 2412- 2414. doi:10.1212/WNL.43.11.2412-a
[16] Maksimovich, I.V. and Gotman, L.N. (2006) Method of complex radiation diagnostics at pre-clinical and clinical stages of Alzheimer’s disease. Russian Patent, No. 2315559. http://bankpatentov.ru/node/28577
[17] Maksimovich, I.V., Gotman, L.N. and Masyuk, S.M. (2006) Method of determining dimensions of temporal brain lobes in patients suffering from Alzheimer’s disease. Russian Patent, No. 2306102. http://worldwide.espacenet.com/publicationDetails/biblio?DB=EPO-DOC&adjacent=true&locale=en_EP&FT=D&date=20070920&CC=RU&NR=2306102C1&KC=C1
[18] Maksimovich, I.V. (2009) Possibilities of modern computed tomography of brain in Alzheimer’s disease diag- nosis. The Neurologic Bulletin, 1, 5-10. http://www.infamed.com/nb/1_2009_5-10.pdf
[19] Maksimovich, I.V. (2011) Dyscirculatory angiopathy of Alzheimer’s type. Journal of Behavioral and Brain Science, 1, 57-68. doi:10.4236/jbbs.2011.12008
[20] Burton, E.J., Barber, R.E., Mukaetova-Ladinska, B., Robson, J., Perry, R.H., Jaros, E., Kalaria, R.N. and O’Brien, T.J. (2009) Medial temporal lobe atrophy on MRI differentiates Alzheimer’s disease from dementia with Lewy bodies and vascular cognitive impairment: A prospective study with pathological verification of diagnosis. Brain, 132, 195-203. http://www.ncbi.nlm.nih.gov/pubmed?term=%E2%80%9CMdial%20temporal%20lobe%20atrophy%20on%20MRI%20differentiates%20Alzheimer's%20disease%20from%20demetia%20with%2
[21] Maksimovich, I.V. and Polyaev, Yu.A. (2010) The Importance of early diagnosis of dyscircular angiopathy of Alzheimer’s type in the study of heredity of Alzheimer’s disease. Alzheimer’s & Dementia, 6, e43. http://download.journals.elsevierhealth.com/pdfs/journals/1552-5260/PIIS1552526010023253.pdf
[22] Dickerson, B.C. (2006) Functional magnetic resonance imaging of cholinergic modulation in mild cognitive impairment. Current Opinion in Psy-chiatry, 19, 299-306. doi:10.1097/01.yco.0000218602.25346.c6
[23] Chiang, G.C., Insel, Ph.S., Tosun, D., Schuff, N., Truran- Sacrey, D., Raptentsetsang, S., Jack, C.R. and Weiner, M.W. (2011) Identifying cognitively healthy elderly individuals with subsequent memory decline by using automated MR temporoparietal volumes. Radiology, 259, 844-851. doi:10.1148/radiol.11101637
[24] Schuff, N., Insel, Ph., Chiang, G., Truran, D., Gamst, A., Jack, C., Aisen, P., Petersen, R., Shaw, L., Trojanowski, J. and Weiner, M. (2011) Acceleration of brain atrophy rates with advancing cognitive deterioration from normal aging to MCI to Alzheimer’s disease. Alzheimer’s & Dementia, 7, S223. http://www.alzheimersanddementia.com/article/S1552-5260(11)00765-5/fulltext
[25] Trojanowski, J.Q., Vandeerstichele, H., Korecka, M., et al. (2010) Update on the biomarker core of the Alzheimer’s disease neuroimaging initiative subjects. Alzheimer’s & Dementia, 6, 230-238. http://www.ncbi.nlm.nih.gov/pubmed/20451871
[26] Meyer, P.T., Hellwig, S., Amtage, F., et al. (2011) Dual-biomarker imaging of regional cerebral amyloid load and neuronal activity in dementia with PET and 11C-labeled Pitts-burgh compound B. Journal of Nuclear Medicine, 52, 393-400. doi:10.2967/jnumed.110.083683
[27] Perrin, R.J., Craig-Schapiro, R., Morris, J.C., et al. (2011) Identification and validation of novelcerebrospinal fluid biomarkers for staging early Alzheimer’s disease. Public Library of Science, 12, e16032. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3020224/?tool=pmcentrez
[28] Jack, C., Vemuri, P.H., Viste, H., et al. (2011) Ordering of Alzheimer’s disease biomarkers. Alzheimer’s & Dementia, 7, S4-S5. doi:10.1016/j.jalz.2011.05.011
[29] De la Torre, J.C. (2012) A turning point for Alzheimer’s disease? Biofactors, 38, 78-83. doi:10.1002/biof.200
[30] Maksimovich, I.V. (2012) The tomography dementia rating scale—Morphologicalli determined scale of Alzheimer’s disease stages. http://www.alzheimersanddementia.com/article/S1552-5260(12)01059-X/fulltext
[31] Folstein, M.F., Folstein, S.E. and McHugh, P.R. (1975) Mini-mental state. A practical method for grading the cognitive state of patients for the clinician. Journal of Psychiatric Research, 12, 189-198. doi:10.1016/0022-3956(75)90026-6
[32] Maksimovich, I.V. (2010) Dyscirculatory angiopathy of the brain of Alzheimer’s type. Alzheimer’s & Dementia, 6, e34. http://www.alzheimersanddementia.com/article/S1552-5260(10)02300-9/fulltext?articleId=&articleTitle=&citedBy=false&isTabularSearchRequestOnSearchResult-Page=no&medlinePmidWithoutMDLNPrefix=&overridingDateRestric-tion=&related=false&restrictdesc_author=&restr
[33] Maksimovich, I.V. (2012) Endovascular application of low-energy laser in the treatment of dyscirculatory angiopathy of Alzheimer’s type. Journal of Behavioral and Brain Science, 2, 67-81. doi:10.4236/jbbs.2012.21008
[34] (2012) Alzheimer’s Association International Conference in Vancouver, British Columbia, Canada, 14-19 July 2012. http://www.alz.org/research/funding/partnerships/ww-adni_overview.asp

comments powered by Disqus

Copyright © 2014 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.